Headquarters: Holon, Israel
Investor Relations: Yvonne Naughton, PhD / +1 (628) 241-0071 / ir@cgen.com

Description
Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen’s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors.
Industry
Life Sciences
Year Founded
Website
Ownership
Public
Exchange / Symbol
NYSE: CGEN